Cargando…

Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients

Very few reports have been published to date on the bloodstream infections caused by Saccharomyces spp. in oncohaematological patients, and there are no guidelines on the use of this probiotic microorganism in this population. We describe the use of probiotic preparation containing Saccharomyces bou...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulik-Tyszka, Beata, Snarski, Emilian, Niedźwiedzka, Magda, Augustyniak, Małgorzata, Myhre, Thorvald Nilsen, Kacprzyk, Anna, Swoboda-Kopeć, Ewa, Roszkowska, Marta, Dwilewicz-Trojaczek, Jadwiga, Jędrzejczak, Wiesław Wiktor, Wróblewska, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973998/
https://www.ncbi.nlm.nih.gov/pubmed/28948565
http://dx.doi.org/10.1007/s12602-017-9332-4
_version_ 1783326724423942144
author Sulik-Tyszka, Beata
Snarski, Emilian
Niedźwiedzka, Magda
Augustyniak, Małgorzata
Myhre, Thorvald Nilsen
Kacprzyk, Anna
Swoboda-Kopeć, Ewa
Roszkowska, Marta
Dwilewicz-Trojaczek, Jadwiga
Jędrzejczak, Wiesław Wiktor
Wróblewska, Marta
author_facet Sulik-Tyszka, Beata
Snarski, Emilian
Niedźwiedzka, Magda
Augustyniak, Małgorzata
Myhre, Thorvald Nilsen
Kacprzyk, Anna
Swoboda-Kopeć, Ewa
Roszkowska, Marta
Dwilewicz-Trojaczek, Jadwiga
Jędrzejczak, Wiesław Wiktor
Wróblewska, Marta
author_sort Sulik-Tyszka, Beata
collection PubMed
description Very few reports have been published to date on the bloodstream infections caused by Saccharomyces spp. in oncohaematological patients, and there are no guidelines on the use of this probiotic microorganism in this population. We describe the use of probiotic preparation containing Saccharomyces boulardii in a large group of oncohaematological patients. We retrospectively analysed the data from 32,000 patient hospitalisations at the haematological centre during 2011–2013 (including 196 haematopoietic stem cell transplant recipients) in a tertiary care university-affiliated hospital. During the study period, 2270 doses of Saccharomyces boulardii probiotic were administered to the oncohaematological patients. In total, 2816 mycological cultures were performed, out of which 772 (27.4%) were positive, with 52 indicating digestive tract colonisation by Saccharomyces spp., mainly in patients with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) or multiple myeloma (MM). While colonised, they were hospitalised for 1683 days and 416 microbiological cultures of their clinical samples were performed. In the studied group of patients, there were six blood cultures positive for fungi; however, they comprised Candida species: two C. glabrata, one C. albicans, one C. krusei, one C. tropicalis and one C. parapsilosis. There was no blood culture positive for Saccharomyces spp. Our study indicates that despite colonisation of many oncohaematological patients with Saccharomyces spp., there were no cases of fungal sepsis caused by this species.
format Online
Article
Text
id pubmed-5973998
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-59739982018-06-08 Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients Sulik-Tyszka, Beata Snarski, Emilian Niedźwiedzka, Magda Augustyniak, Małgorzata Myhre, Thorvald Nilsen Kacprzyk, Anna Swoboda-Kopeć, Ewa Roszkowska, Marta Dwilewicz-Trojaczek, Jadwiga Jędrzejczak, Wiesław Wiktor Wróblewska, Marta Probiotics Antimicrob Proteins Article Very few reports have been published to date on the bloodstream infections caused by Saccharomyces spp. in oncohaematological patients, and there are no guidelines on the use of this probiotic microorganism in this population. We describe the use of probiotic preparation containing Saccharomyces boulardii in a large group of oncohaematological patients. We retrospectively analysed the data from 32,000 patient hospitalisations at the haematological centre during 2011–2013 (including 196 haematopoietic stem cell transplant recipients) in a tertiary care university-affiliated hospital. During the study period, 2270 doses of Saccharomyces boulardii probiotic were administered to the oncohaematological patients. In total, 2816 mycological cultures were performed, out of which 772 (27.4%) were positive, with 52 indicating digestive tract colonisation by Saccharomyces spp., mainly in patients with acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) or multiple myeloma (MM). While colonised, they were hospitalised for 1683 days and 416 microbiological cultures of their clinical samples were performed. In the studied group of patients, there were six blood cultures positive for fungi; however, they comprised Candida species: two C. glabrata, one C. albicans, one C. krusei, one C. tropicalis and one C. parapsilosis. There was no blood culture positive for Saccharomyces spp. Our study indicates that despite colonisation of many oncohaematological patients with Saccharomyces spp., there were no cases of fungal sepsis caused by this species. Springer US 2017-09-25 2018 /pmc/articles/PMC5973998/ /pubmed/28948565 http://dx.doi.org/10.1007/s12602-017-9332-4 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Sulik-Tyszka, Beata
Snarski, Emilian
Niedźwiedzka, Magda
Augustyniak, Małgorzata
Myhre, Thorvald Nilsen
Kacprzyk, Anna
Swoboda-Kopeć, Ewa
Roszkowska, Marta
Dwilewicz-Trojaczek, Jadwiga
Jędrzejczak, Wiesław Wiktor
Wróblewska, Marta
Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
title Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
title_full Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
title_fullStr Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
title_full_unstemmed Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
title_short Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
title_sort experience with saccharomyces boulardii probiotic in oncohaematological patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973998/
https://www.ncbi.nlm.nih.gov/pubmed/28948565
http://dx.doi.org/10.1007/s12602-017-9332-4
work_keys_str_mv AT suliktyszkabeata experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT snarskiemilian experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT niedzwiedzkamagda experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT augustyniakmałgorzata experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT myhrethorvaldnilsen experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT kacprzykanna experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT swobodakopecewa experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT roszkowskamarta experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT dwilewicztrojaczekjadwiga experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT jedrzejczakwiesławwiktor experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients
AT wroblewskamarta experiencewithsaccharomycesboulardiiprobioticinoncohaematologicalpatients